MONOPAR THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5981 USD | -8.13% |
|
-20.25% | +75.81% |
| 09/05 | Monopar Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 16/04 | Monopar Therapeutics Files Provisional Patent for New MNPR-101 Construct | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 173 | 70.09 | 40.42 | 30.62 | 5.058 | 10.44 | - | - |
| Enterprise Value (EV) 1 | 173 | 70.09 | 40.42 | 30.62 | 5.058 | 10.44 | 10.44 | 10.44 |
| P/E ratio | - | -10.6 x | -4.4 x | -2.86 x | -0.56 x | -1.64 x | -1.9 x | -2.17 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 10,421 | 11,452 | 12,591 | 12,920 | 14,866 | 17,455 | - | - |
| Reference price 2 | 16.60 | 6.120 | 3.210 | 2.370 | 0.3402 | 0.5981 | 0.5981 | 0.5981 |
| Announcement Date | 27/03/20 | 25/03/21 | 24/03/22 | 23/03/23 | 28/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -4.324 | -6.509 | -9.127 | -10.54 | -8.831 | -6.69 | -9.369 | -9.865 |
| Operating Margin | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -6.305 | -9.103 | -10.52 | -8.402 | -6.535 | -9.353 | -11.6 |
| Net income 1 | - | -6.305 | -9.103 | -10.52 | -8.402 | -6.535 | -9.235 | -8.898 |
| Net margin | - | - | - | - | - | - | - | - |
| EPS 2 | - | -0.5800 | -0.7300 | -0.8300 | -0.6100 | -0.3650 | -0.3150 | -0.2750 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 27/03/20 | 25/03/21 | 24/03/22 | 23/03/23 | 28/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -2.681 | -2.457 | -2.763 | -2.407 | -2.909 | -2.525 | -2.328 | -2.066 | -1.912 | -1.723 | -1.62 | -1.655 | -1.691 | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -15.53 | -2.457 | -2.763 | -2.4 | -2.896 | -2.435 | -2.2 | -1.954 | -1.814 | -1.641 | -1.588 | -1.63 | -1.676 | - | - |
| Net income 1 | -15.53 | -2.457 | -2.763 | -2.4 | -2.896 | -2.435 | -2.2 | -1.954 | -1.814 | -1.641 | -1.588 | -1.63 | -1.676 | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.2100 | -0.1900 | -0.2200 | -0.1900 | -0.2300 | -0.1900 | -0.1600 | -0.1400 | -0.1200 | -0.1000 | -0.0900 | -0.0967 | -0.0933 | -0.0900 | -0.0900 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 24/03/22 | 12/05/22 | 11/08/22 | 10/11/22 | 23/03/23 | 11/05/23 | 10/08/23 | 09/11/23 | 28/03/24 | 09/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 27/03/20 | 25/03/21 | 24/03/22 | 23/03/23 | 28/03/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.5981
USD
Average target price
2.08
USD
Spread / Average Target
+247.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +75.81% | 1.04Cr | |
| +29.77% | 4.95TCr | |
| +1.00% | 4.26TCr | |
| +50.47% | 4.25TCr | |
| -5.26% | 2.91TCr | |
| +13.68% | 2.66TCr | |
| -22.99% | 1.86TCr | |
| +8.22% | 1.32TCr | |
| +32.41% | 1.25TCr | |
| -1.62% | 1.2TCr |
- Stock Market
- Equities
- MNPR Stock
- Financials Monopar Therapeutics Inc.